Bristol Myers Squibb Company $BMY Shares Acquired by Munich Reinsurance Co Stock Corp in Munich

Munich Reinsurance Co Stock Corp in Munich boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 9.8% in the 2nd quarter, Holdings Channel reports. The firm owned 347,582 shares of the biopharmaceutical company’s stock after purchasing an additional 31,048 shares during the period. Munich Reinsurance Co Stock Corp in Munich’s holdings in Bristol Myers Squibb were worth $20,028,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Blalock Williams LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter worth $280,000. Three Seasons Wealth LLC boosted its stake in shares of Bristol Myers Squibb by 63.1% during the second quarter. Three Seasons Wealth LLC now owns 38,187 shares of the biopharmaceutical company’s stock worth $2,200,000 after buying an additional 14,778 shares during the period. Tudor Financial Inc. boosted its stake in shares of Bristol Myers Squibb by 250.8% during the second quarter. Tudor Financial Inc. now owns 5,318 shares of the biopharmaceutical company’s stock worth $306,000 after buying an additional 3,802 shares during the period. Sapient Capital LLC grew its holdings in shares of Bristol Myers Squibb by 1.0% during the second quarter. Sapient Capital LLC now owns 37,372 shares of the biopharmaceutical company’s stock worth $2,153,000 after buying an additional 364 shares during the last quarter. Finally, Syon Capital LLC increased its position in Bristol Myers Squibb by 15.2% in the 2nd quarter. Syon Capital LLC now owns 16,588 shares of the biopharmaceutical company’s stock valued at $956,000 after acquiring an additional 2,193 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $66.85 on Friday. The stock has a market capitalization of $136.56 billion, a price-to-earnings ratio of 14.72, a PEG ratio of 0.32 and a beta of 0.23. The business’s 50 day moving average is $62.92 and its two-hundred day moving average is $59.92. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a Phase 2 trial evaluating a therapy in depression, expanding its pipeline into a large potential market. Positive clinical progress could provide a new growth opportunity if the treatment demonstrates efficacy and safety. Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, roughly 3.7% forward dividend yield, strong margins and growth products that are offsetting declines in older medicines. These factors support the stock’s defensive and income-oriented appeal. Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
• Neutral Sentiment: Technical indicators have reportedly turned bullish, while RBC Capital maintained a Hold rating, indicating that analysts see some upside but remain cautious about the company’s outlook. Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
• Negative Sentiment: Bristol Myers Squibb paused enrollment in its zola-cel autoimmune cell-therapy trials after safety surveillance identified inflammatory side effects. Reports that the pause involved serious safety concerns raised questions about the program’s risk profile, development timeline and broader cell-therapy strategy. What Does Bristol Myers Squibb Trial Pause Mean For Its Pipeline?
• Negative Sentiment: The wider healthcare sector traded lower, adding industry-level pressure to BMY. Investors also continue to monitor legacy-drug declines, including Opdivo, and future Eliquis patent-expiry risks. Sector Update: Healthcare Stocks Decline Friday Afternoon

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by company insiders.

Analysts Set New Price Targets

BMY has been the subject of a number of recent research reports. Roth Capital initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective for the company. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Raymond James Financial assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, Royal Bank Of Canada boosted their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.